Objectives-We compared the complications and diagnostic adequacy of ultrasound (US)-guided core needle biopsy (CNB) for head and neck mass lesions between patients who did and did not receive antiplatelet/anticoagulation therapy.
necrotic lesions. [1] [2] [3] [4] In addition, lymphomas, salivary gland malignancy, and nonepithelial neoplasms are inaccurately diagnosed on FNAC because immunohistochemical staining is crucial for the definitive diagnosis and determination of their subtypes. Conventionally, open surgical biopsy or mass excision is the reference standard for diagnosis and can provide a specific diagnosis in such cases. 1 Ultrasound-guided core needle biopsy (CNB) has gained acceptance as a complementary method with US-guided FNAC and an alternative method for open surgical biopsy. 1, [5] [6] [7] Because CNB can harvest sufficient tissues, even from heavily calcified or fibrotic lesions by using an automatic device, and can provide a histologic sample that retains its cytologic characteristics and tissue architecture, which aids in immunohistochemical staining for diagnosis, its sampling adequacy and diagnostic accuracy have been reported as superior to those of FNAC for various head and neck mass lesions. 1, 5, 6, [8] [9] [10] However, there are several concerns regarding CNB, including the possibility of tumor seeding and complications of bleeding/hematoma. In a recent study on the diagnostic role of CNB in cervical lymphadenopathy, CNB was not recommended as a first-line biopsy technique in patients older than 40 years, who are more likely to have metastatic lymphadenopathy and a higher risk of tumor seeding compared with younger patients. 9 Furthermore, the risk of bleeding/hematoma is greater with CNB because of the use of large-bore needles or the requirement of needle firing to obtain tissue. In a meta-analysis and systematic review regarding the role of US-guided CNB in the diagnosis of head and neck lesions, only 13 (1.0%) minor hematomas were reported in a total of 1291 biopsies, with no major bleeding requiring further treatment. 1 However, in most previous studies on CNB, patients undergoing antiplatelet/anticoagulation therapy were excluded, or the therapy was withheld for several days before the procedure. [11] [12] [13] Therefore, no study has verified the safety of USguided CNB for head and neck mass lesions in patients undergoing antiplatelet/anticoagulation therapy. In clinical practice, however, patients with head and neck mass lesions occasionally exhibit comorbidities requiring chronic antiplatelet/anticoagulation therapy. 14, 15 Although routine discontinuation of the antiplatelet/anticoagulation therapy before CNB may be recommended, it exposes the patient to the risk of a thromboembolic event, whereas continuation of the therapy predisposes the patients to a higher risk of bleeding after CNB. 16 Given the recently increasing popularity of CNB as a diagnostic modality for head and neck mass lesions, it has become necessary to determine the safety of CNB in such patients who are undergoing antiplatelet/anticoagulation therapy. However, the sole verification of safety is not adequate to support the use of CNB in the presence of antiplatelet/anticoagulation therapy, although it should be the first consideration. The diagnostic adequacy of CNB in these patients should also be addressed, since antiplatelet/ anticoagulation therapy may potentially be associated with a higher bleeding tendency and thereby unsatisfactory specimens. Therefore, we performed this preliminary study to evaluate the safety and diagnostic adequacy of US-guided CNB for various head and neck mass lesions in patients undergoing antiplatelet/ anticoagulation therapy.
Materials and Methods

Patients
This study was designed as a prospective case study from a single center. The Institutional Review Board of our hospital approved the study protocol, and written informed consent to undergo the procedures and for study enrollment was obtained from all patients (registration number 201410024).
We enrolled a total of 146 consecutive patients who underwent US-guided CNB for head and neck mass lesions between March 2013 and December 2015. Of these patients, 32 were receiving antiplatelet/anticoagulation therapy, and 114 were not. The indications for antiplatelet/anticoagulation therapy were a cardiovascular event in 24 patients, cerebrovascular event in 6, and deep venous thrombosis/pulmonary thromboembolism in 2. The antiplatelet/anticoagulation drugs used included aspirin in 18 patients, clopidogrel in 6, cilostazol in 3, and warfarin in 5.
The indications for US-guided CNB were inconclusive results such as unsatisfactory specimens and undetermined findings from previous US-guided FNAC procedures and discordance between US and FNAC findings (suspicious mass on US imaging with benign cytologic results from previous US-guided FNAC). The observation of malignancy or suspected malignancy with an undetermined cell type on previous US-guided FNAC was also an indication for US-guided CNB to confirm the malignancy and determine the specific subtype.
For the patients receiving antiplatelet/anticoagulation therapy, we explained both the benefits and risks of continuing or discontinuing the medication before CNB before enrolment in the study.
Ultrasound-Guided CNB All US-guided CNB procedures included in the study were performed in the outpatient department by a single head and neck surgeon (D.A.) with 9 years of experience in interventional procedures for the head and neck region. An HD7 US system (Philips Healthcare, Bothell, WA) with a high-frequency 5-12-MHz linear transducer was used for all procedures. Core needle biopsy was performed by the same procedures followed in our previous study (in which D.A. was the surgeon). 7 A disposable 18-gauge double-action spring-activated needle with a 1.1-cm excursion length (TSK Ace-cut; Create Medic, Yokohama, Japan) was used for CNB in all patients to eliminate any bias owing to the needle size.
The patient was placed in the supine position with the neck extended and head rotated if required. As the operator in this study was right handed, CNB for right neck lesions was performed at the right side of the patients, whereas CNB for left neck lesions was performed at the left side of the patients. After the administration of local anesthesia consisting of 1% lidocaine mixed with 1:100,000 epinephrine around the target lesion and along the path of biopsy under real-time US monitoring, the core needle was inserted into the skin in a parallel fashion and advanced toward the margin of or into the mass under real-time US monitoring. We did not use a skin incision to facilitate insertion of the needle or a biopsy guide device. After the biopsy route was confirmed, the stylet and cutting cannula of the needle were sequentially fired. Generally, the core needle was passed twice; however, up to 4 needle passes were performed in patients suspected to have lymphomas to collect adequate specimens for special staining. After the procedure, the biopsy site was immediately compressed manually for 20 to 30 minutes, and sequential US examinations were routinely performed to identify early bleeding/hematoma. Patients were recalled 5 to 10 days after US-guided CNB to inform them about the biopsy results, and follow-up US examinations were performed at that time to identify delayed bleeding/hematoma or any change in initial bleeding/hematoma that occurred at the time of US-guided CNB.
Assessment Parameters
According to the study protocol, patient age and sex and mass location, side, size, and characteristics, such as the proportion of solid components, vascularity, and calcifications, on US imaging were recorded at the time of US-guided CNB. The proportion of solid components was categorized into predominantly solid, mixed, and predominantly cystic. The vascularity of the mass lesion was categorized as none to low, intermediate, and high. Calcifications were categorized as no calcifications, microcalcifications, macrocalcifications, and rim calcifications. Complications and adverse reactions after CNB, such as bleeding/hematoma, bruising at the needle insertion site, injury to the recurrent laryngeal nerve, trachea, esophagus, and other cranial nerves, numbness in the neck, and pain during the procedure, were evaluated immediately after CNB and at the follow-up visit. Bleeding/hematoma was categorized as clinical and subclinical. Clinical bleeding/hematoma was defined as bleeding/hematoma identified on a US examination and resulting in subjective signs/symptoms, thus requiring a therapeutic intervention or close observation. Subclinical bleeding/hematoma was defined as bleeding/hematoma with no subjective signs/symptoms that was identified only on a US examination, thus requiring no treatment or hospitalization. For patients with bleeding/hematoma, we measured the volume of the developed bleeding/hematoma on US imaging by using the ellipsoid formula (length 3 width 3 depth 3 0.52), assuming that the hematoma was ellipsoid. Pain was assessed by mean visual analog scale (VAS) scores. For all patients, the pathologic findings obtained from CNB specimens were compared with those obtained from previous FNAC specimens. For statistical analysis of the parameters, P < .05 was considered significant.
Results
Patient Characteristics
The baseline characteristics of the enrolled patients from both groups are listed in Table 1 . The mean age was significantly higher in the antiplatelet/anticoagulation group than in the no-antiplatelet/anticoagulation group. However, other characteristics were not significantly different. In the 5 patients receiving warfarin, the most recent mean prothrombin time and international normalized ratio were 25.5 seconds (range, 22.9-29.1 seconds) and 2.4 (range, 2.11-2.70), respectively. However, in the 27 patients undergoing antiplatelet therapy, we did not perform these laboratory tests because they do not reflect platelet function.
Complications of US-Guided CNB
The complications of US-guided CNB for head and neck mass lesions in patients with and without antiplatelet/anticoagulation therapy are listed in Table 2 . The mean number of needle passes was not different between the no-antiplatelet/anticoagulation and antiplatelet/anticoagulation groups. Clinical bleeding/hematoma did not occur in any patient in both groups. The incidence of subclinical bleeding/hematoma ( Figure 1 ) and mean volume of the subclinical bleeding/hematoma were not significantly different between the groups.
Among the 18 patients who developed subclinical bleeding/hematoma from both groups, the mean volume was 3.0 mL (range, 0.9-5.7 mL), as measured by US.
Bruising at the needle insertion site was significantly different between the groups. Although some patients in both groups had pain during the CNB procedure, the difference was not statistically significant. The mean VAS scores for pain were not statistically significant. Injury to critical structures, such as the recurrent laryngeal nerve, trachea, esophagus, and other cranial nerves, was not observed in any patient in either group.
In addition, we reanalyzed the data after reclassifying patients receiving aspirin (n 5 18) into the no-antiplatelet/anticoagulation therapy group. The incidence of complications, including bleeding/hematoma, bruising at the needle insertion site, injury to critical structures, and pain, was not significantly different compared with the remaining patients in the antiplatelet/anticoagulation therapy group (n 5 14) who received clopidogrel, cilostazol, or warfarin (Table 3) .
Diagnostic Adequacy and Pathologic Findings of US-Guided CNB Adequate specimens were obtained by US-guided CNB from 144 (98.6%) of the 146 patients, resulting in an overall unsatisfactory sampling rate of 1.4%. The unsatisfactory sampling rates were 1.8% (2 of 114) and 0.0% (0 of 32) for the no-antiplatelet/anticoagulation and antiplatelet/anticoagulation groups, respectively, with no significant difference between the groups (P > .999). The unsatisfactory sampling rates were also not different according to the laterality of the lesion, with 1.4% (1 of 70) in right neck lesions and 1.5% (1 of 68) in left neck lesions (P > .999). Undetermined results that could not aid in the differentiation between benign and malignant lesions were obtained for 14 (12.3%) patients in the noantiplatelet/anticoagulation group and 0 (0.0%) patients in the antiplatelet/anticoagulation group, with a statistically significant difference between the groups (P 5 .040). However, excluding the 10 patients with follicular neoplasms, for which it is not possible to differentiate between benign and malignant lesions by using FNAC and CNB without surgery, only 4 (3.5%) patients in the no-antiplatelet/anticoagulation group showed undetermined results, with no significant difference between the groups (P 5 .576). Core needle biopsy differentiated benign and malignant lesions for 98 (86.0%) patients in the no-antiplatelet/anticoagulation group. The definitive or suspicious subtype of the lesion, which aids in establishing an appropriate treatment plan, was determined for 92 of the 98 patients. For 2 patients, although malignancy was diagnosed, the subtypes could not be specified by CNB alone, whereas in the remaining 4 patients, although lymphoma was diagnosed, the subtype could not be specified by CNB alone. Benign and Figure 1 . Representative images of a subclinical hematoma after US-guided CNB. A US examination shows a 0.9-cm right thyroid nodule (A) with evident hypervascularity (B). After CNB, a minor hematoma (asterisk) with no related signs/symptoms is identified on a sequential US examination (C). Data are presented as mean (range) and number (percent) where applicable.
Ahn et al-US-Guided Core Needle Biopsy Under Anticoagulation Therapy malignant lesions were differentiated by US-guided CNB for all 32 patients in the antiplatelet/anticoagulation group, whereas the definitive or suspicious subtype was determined in 30. In 1 patient, although carcinoma was diagnosed, its subtype could not be specified by CNB alone, whereas in the remaining patient, although thyroid carcinoma was diagnosed, CNB could not differentiate between anaplastic thyroid carcinoma and poorly differentiated carcinoma.
Discussion
In this preliminary study, we showed that US-guided CNB can be performed safely without the discontinuation of antiplatelet/anticoagulation therapy in patients with head and neck mass lesions. Although patients undergoing antiplatelet/anticoagulation therapy had a higher frequency of skin bruising, there was no case of clinical bleeding/hematoma. In addition, the incidence of subclinical bleeding/hematoma and volume of the developed subclinical bleeding/hematoma were not significantly different between patients who did and did not receive antiplatelet/anticoagulation therapy. Furthermore, even when patients receiving aspirin were classified as part of the noantiplatelet/anticoagulation therapy group, there was no significant difference in the incidence of subclinical bleeding/hematoma and mean volume of subclinical bleeding/hematoma between the groups. Although the overall incidence of subclinical bleeding/hematoma was relatively high (12.4%) in our study population, it can be attributed to the prospective assessment of complications using routine US examinations immediately after US-guided CNB, even in patients with no signs/symptoms of bleeding/ hematoma. With regard to major invasive procedures, we do not disagree that the risk of bleeding/hematoma was higher in the antiplatelet/anticoagulation group than that in the no-antiplatelet/anticoagulation group. However, the results of our study suggest that, when performed by experienced hands with caution, US-guided CNB is not a major invasive procedure that can increase bleeding complications in the presence of antiplatelet/ anticoagulation therapy. In fact, studies on breast CNB have reported that there was no difference in the incidence of bleeding complications after CNB between patients with and without antiplatelet/anticoagulation therapy. 17, 18 Considering that breast CNB is performed with 9-to 14-gauge needles, the size of the needle used for head and neck CNB, which is 16 to 18 gauge, appears relatively small to substantially increase the risk of bleeding/hematoma, even in patients undergoing antiplatelet/anticoagulation therapy. Moreover, data from patients who underwent cutaneous and dental surgical procedure, which are more invasive than CNB, have shown that antiplatelet/anticoagulation therapy does not increase the risk of bleeding associated with the procedures. 19, 20 In addition to the modest invasiveness of CNB itself, appropriate management around the CNB procedure, such as the routine use of local infiltration using lidocaine mixed with epinephrine before CNB and manual compression for 20 to 30 minutes immediately after CNB, may also aid in local hemostasis, even in the presence of antiplatelet/anticoagulation therapy. This factor could be a reason for the lack of a significant difference in the incidence of bleeding/hematoma between patients with and without antiplatelet/anticoagulation therapy. 18 Therefore, we do not recommend routine discontinuation of antiplatelet/anticoagulation therapy and a delay in CNB merely because of a concern for bleeding complications because it is unnecessarily timeand cost-consuming and can increase the risk of thromboembolic events in some patients. Instead, the decision of continuing or discontinuing antiplatelet/anticoagulation therapy should be made after considering the possible advantages and disadvantages of continuation/ discontinuation, the diagnostic urgency, and the severity of the patient's underlying comorbidities. If biopsy is urgently required and there is a substantial risk associated with antiplatelet/anticoagulation therapy discontinuation, we recommend that it is feasible and reasonable to cautiously proceed with CNB. 17 However, this study involved only a subset of the various available antiplatelet/anticoagulation drugs; thus, the results and relevance of the study should be limited only to cases involving the evaluated antiplatelet/anticoagulation drugs.
Regardless of the use of antiplatelet/anticoagulation therapy, we believe that the vascularity of the mass lesions was primarily associated with the development of subclinical bleeding/hematoma. In a comparison of mass vascularity between 128 patients with no bleeding/ hematoma and 18 with subclinical bleeding/hematoma, the latter group showed a trend toward a higher rate of intermediate and high vascularity than the former, with a moderately significant result (32.2% versus 50.0%; P 5 .092). However, we did not include this aspect in our analysis because all bleeding/hematomas were subclinical cases that had little clinical significance.
In addition to safety, studies on FNAC or CNB in patients undergoing antiplatelet/anticoagulation therapy were also concerned with the diagnostic adequacy of these procedures, considering that the predisposition of these patients to bleed during the procedures may not allow for adequate specimen harvesting and can obscure the target lesion during real-time US monitoring. 17, 21 A recent study of US-guided FNAC for thyroid nodules in 129 and 309 patients with and without antiplatelet/anticoagulation therapy, respectively, showed that the incidence of unsatisfactory cytologic results was not different between the groups (2.3% in the no antiplatelet/anticoagulation group versus 3.9% in the antiplatelet/anticoagulation group; P 5 .350). The authors concluded that the discontinuation of antiplatelet/anticoagulation therapy is not necessary to obtain sufficient specimens for diagnosis. 21 Similarly, our study on USguided CNB for various head and neck mass lesions showed no differences in the unsatisfactory sampling rate between patients with and without antiplatelet/anticoagulation therapy. Furthermore, specific diagnostic information that permitted the surgeon to establish an appropriate treatment plan was provided for 30 (93.8%) of the 32 patients in the antiplatelet/anticoagulation group. These patients did not require additional open biopsy for pure diagnostic purposes. However, in our experience, the target mass became gradually blurred with an increase in the number of needle passes during real-time US monitoring, particularly in patients receiving antiplatelet/anticoagulation therapy. This finding was possibly because of intratumoral hemorrhage. For this reason, we deem that accurate targeting and obtaining sufficient tissue in the first or second needle pass are very important for a high rate of adequate sampling in patients receiving antiplatelet/anticoagulation therapy. However, as long as CNB is performed by technically experienced clinicians who can harvest appropriate tissue within the second needle pass, we believe that antiplatelet/anticoagulation therapy does not affect the sampling adequacy as well as the diagnostic usefulness of CNB for head and neck mass lesions. In fact, considering that most patients with a previous cardiovascular or cerebrovascular history who are undergoing antiplatelet/anticoagulation therapy are high-risk patients for any invasive procedure, the diagnostic usefulness of CNB would be much higher in the presence of antiplatelet/anticoagulation therapy because it allows both open surgical biopsy and general anesthesia, which is often required for open biopsy, to be avoided. Therefore, paradoxically, we deem that CNB would be a better diagnostic alternative before open surgical biopsy in patients undergoing antiplatelet/anticoagulation therapy rather than in those who are not.
Generally, we do not recommend CNB for lesions smaller than 0.5 cm, although 4 lesions smaller than 0.5 cm were included in the study. All of these lesions were heavily calcified and relatively fixed to the adjacent tissue, and we failed to harvest an adequate specimen in more than 2 FNAC procedures. In our experience, the main cause of difficulty in targeting small lesions is their gliding or mobile nature (ie, their tendency to move when inserting the needle into the lesion) rather than the small size itself, which precludes accurate targeting. If the lesion is hard and fixed to adjacent tissue, we believe that the lesion can be targeted accurately by CNB with no great difficulties, even when the lesion is relatively small. To reduce the gliding movement or mobility of the lesion when the needle was inserted, we had an assistant stretch the circumjacent skin around the lesion. Furthermore, a relatively small-bore needle, which is more suitable for small lesions, was used for the procedures.
Because this study was designed as a preliminary study from a single center, it had some limitations. First, we did not have complete information for antiplatelet/ anticoagulation parameters, such as the bleeding time international normalized ratio at the time of procedure and the duration from the last antiplatelet/anticoagulation medication dose. Second, since the cohort for different types of ongoing medication was small, we were unable to determine the impact of each antiplatelet/anticoagulation drug on the development of subclinical bleeding/hematoma. Third, the results of this preliminary study are insufficient to establish the diagnostic accuracy of CNB in patients receiving antiplatelet/anticoagulation therapy. The number of patients in the antiplatelet/anticoagulation group was relatively small, and subsequent surgery was performed only for a subset of patients whose biopsy results and symptoms indicated the need for surgical intervention, thus precluding calculation of the sensitivity, specificity, positive predictive value, and negative predictive value for the antiplatelet/ anticoagulation group.
In conclusion, the results of our study on patients with head and neck mass lesions suggest that antiplatelet/anticoagulation therapy does not increase the complication and unsatisfactory sampling rates for USguided CNB. Therefore, the discontinuation of antiplatelet/anticoagulation therapy before US-guided CNB may be unnecessary when the need for biopsy is urgent and when the risk of complications caused by the discontinuation of antiplatelet/anticoagulation therapy is high. However, because this work was a preliminary study, the study population was relatively small. Therefore, further studies involving a larger number of patients should be performed to confirm the results of this study.
